Risk and reward often travel hand-in-hand, making the stock market both lucrative and dangerous. Among the best exemplars of this axiom are the …
Dark clouds are looming over Wall Street, and the storm only appears to be intensifying. The market was dealt another blow on Wednesday …
Shares of biotechnology company AcelRx (ACRX) are tumbling – down nearly 17% as of this writing. The reason?
On a day like today, when the entire stock market is under pressure, you must have done something right to see your stock …
Drug company AcelRx (ACRX) is likely celebrating its first win after getting news from the Food and Drug Administration (FDA) late Friday afternoon …
Investors are jumping in and out ahead of a Food and Drug Administration (FDA) decision on AcelRx’s (ACRX) opioid pain drug Dsuvia, with …
Acelrx’s (ACRX) shares popped over 20% in pre-market trading Monday, following indications that the U.S.
Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX) and AcelRx Pharmaceuticals (ACRX) look forward to important regulatory approval decisions this year. Could these catalysts give these small …
The Food and Drug Administration (FDA) is scheduled to hold an advisory committee meeting on Friday to review AcelRx’s (ACRX) pain medication Dsuvia. …
Not everyone is excited about AcelRx Pharmaceuticals (NASDAQ:ACRX), which focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute …
